MaxCyte, Inc. (LON:MXCT - Get Free Report) shares reached a new 52-week low on Wednesday . The stock traded as low as GBX 182 ($2.40) and last traded at GBX 183 ($2.41), with a volume of 82541 shares traded. The stock had previously closed at GBX 197 ($2.60).
MaxCyte Stock Up 1.1 %
The firm has a market cap of £253.45 million, a PE ratio of -7.04 and a beta of 1.13. The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The company's 50 day moving average price is GBX 262.15 and its two-hundred day moving average price is GBX 295.31.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
See Also
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
